Pharmaceuticals

Projected Growth of the Global Cold Chain Temperature Monitoring Market to Reach $1.01 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cold chain temperature monitoring market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Cold Chain Temperature Monitoring Market By The End Of 2029?

The CD40 ligand (CD40L) antibody market has seen substantial growth in recent years. It is projected to expand from $0.63 billion in 2024 to $0.69 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.7%. This historical expansion can be attributed to factors such as the increasing prevalence of autoimmune diseases, a rising demand for targeted cancer treatments, expanding research on immune modulation, regulatory approvals for novel biologics, an increase in healthcare expenditures, and the growing adoption of personalized medicine approaches.

The CD40 ligand (CD40L) antibody market size is anticipated to experience robust expansion in the coming years, with projections indicating a growth to $1.01 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period can be linked to the increasing adoption of personalized medicine, augmented research investments in autoimmune and transplant therapies, a surge in regulatory approvals for innovative treatments, increased understanding of CD40L antibody advantages in organ transplantation, and a rise in clinical trials for immunosuppressive applications. Noteworthy trends for the forecast period include enhancements in antibody engineering, the development of bispecific antibodies for targeted treatments, advancements in delivery techniques, improvements in combination therapies, progress in personalized medicine, and breakthroughs in creating biomarkers for more precise patient selection.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21132&type=smp

Which Business Drivers Are Underpinning The Growth Of The Cold Chain Temperature Monitoring Market?

The increasing occurrence of autoimmune disorders is projected to propel the expansion of the CD40 ligand (CD40L) antibody market moving forward. These conditions develop when the immune system mistakenly attacks the body’s own cells, leading to damage, as observed in rheumatoid arthritis, lupus, and type 1 diabetes. The escalating prevalence of autoimmune disorders is attributable to elements such as environmental triggers, genetic predisposition, alterations in lifestyle, and heightened diagnostic awareness, all of which contribute to an elevated rate of detection and incidence. CD40 Ligand (CD40L) antibodies are emerging as a promising therapeutic strategy for managing autoimmune disorders by modulating the immune system’s overactive response. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency responsible for information and statistics on Australia’s health and welfare, in 2022, an estimated 514,000 Australians (2.0% of the population) were living with rheumatoid arthritis (a type of autoimmune disorders), with 2.5% of females and 1.6% of males affected. Thus, the rising incidences of autoimmune disorders are a significant driver for the growth of the CD40 ligand (CD40L) antibody market.

What Are The Principal Segment Types In The Cold Chain Temperature Monitoring Market?

The cd40 ligand (cd40l) antibody market covered in this report is segmented –

1) By Type: Monoclonal Antibody, Polyclonal Antibody

2) By Application: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Immunoprecipitation, Immunofluorescence, Other Applications

3) By End-User: Hospitals, Research Institutes, Specialty Clinics, Other End-Users

Subsegments:

1) By Monoclonal Antibody: Fully Human Monoclonal Antibodies, Humanized Monoclonal Antibodies, Chimeric Monoclonal Antibodies

2) By Polyclonal Antibody: Rabbit Polyclonal Antibodies, Goat Polyclonal Antibodies, Mouse Polyclonal Antibodies

How Are Industry Trends Steering The Expansion Of The Cold Chain Temperature Monitoring Market?

Leading companies operating within the CD40 ligand (CD40L) antibody market are emphasizing the advancement of clinical trials and the expansion of therapeutic applications. Clinical trials represent systematic investigations conducted to evaluate the safety, efficacy, and optimal utilization of a medical intervention or treatment. For instance, in September 2023, Eledon Pharmaceuticals Inc., a US-based biotechnology company, announced the deployment of Tegoprubart anti-CD40L antibody in a clinical trial following the second-ever genetically modified pig heart transplant; the trial aimed to assess its role in preventing organ rejection and broadening therapeutic applications in organ transplantation. Furthermore, Tegoprubart has also exhibited promise in treating autoimmune diseases through the modulation of immune responses.

Which Companies Are Contributing Significantly To The Cold Chain Temperature Monitoring Market Growth?

Major companies operating in the CD40 ligand (CD40L) antibody market are Thermo Fisher Scientific Co. Ltd., Amgen Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Kiniksa Pharmaceuticals Ltd., BioLegend, Cytek Biosciences Inc., Sino Biological Inc., ACROBiosystems, Elabscience Biotechnology Inc., Cayman Chemical, Eledon Pharmaceuticals, Cell Signaling Technology, Enzo Biochem, GeneTex, GeminiBio, Creative Biolabs, BPS Bioscience Inc., LSBio, MyBiosource Inc., Boster Biological Technology, Bio X Cell, Assay Genie, Abeomics, Leinco Technologies Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cd40-ligand-cd40l-antibody-global-market-report

Which Region Offers The Most Opportunity For Cold Chain Temperature Monitoring Market Expansion?

North America was the largest region in the CD40 ligand (CD40L) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CD40 ligand (CD40L) antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=21132&type=smp

Browse Through More Reports Similar to the Global Cold Chain Temperature Monitoring Market 2025, By The Business Research Company

Antibody Drug Conjugates Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report

Antibody Contract Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

Next Generation Antibody Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795